Several EGFR targeted therapies such as monoclonal antibodies, small molecule inhibitors or RTK inhibitors failed to pass phase II clinical trials of ovarian cancer [59], giving rationale to develop newer therapies. The gene discussed is EGFR; the disease is ovarian carcinoma.